Sarfaraz K. Niazi, PhD, provides an overview of the current biosimilar education material offered by the FDA, emphasizing ...

Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the ...

Sophia Humphreys, PharmD, explains that expanding biosimilars into new therapeutic areas faces hesitance due to maintenance therapies, emphasizing the importance of education, and highlights factors ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

During a recent webinar, experts discussed critical regulatory aspects for generics and biosimilars, highlighting strategies ...

Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex ...

The European Union's (EU) approach to biosimilars has revolutionized the biopharmaceutical market by driving innovation, ...

Ivo Abraham, PhD, RN, director of the Center for Health Outcomes and PharmacoEconomic Research at the University of Arizona ...

Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...

Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study ...

The Biologics Price Competition and Innovation Act (BPCIA) of 2010 initially posed significant barriers to biosimilar ...

A study found that switching from rituximab to biosimilar CT-P10 is safe and effective for patients with systemic lupus ...